vs
安进（AMGN）与Envista Holdings Corp（NVST）财务数据对比。点击上方公司名可切换其他公司
安进的季度营收约是Envista Holdings Corp的13.1倍（$9.9B vs $750.6M）。安进净利率更高（13.5% vs 4.4%，领先9.1%）。Envista Holdings Corp同比增速更快（15.0% vs 8.6%）。安进自由现金流更多（$961.0M vs $91.7M）。过去两年安进的营收复合增速更高（15.1% vs 9.7%）
安进是总部位于美国加利福尼亚州千橡市的跨国生物制药企业，公司名称取自最初的全称「应用分子遗传学」的缩写组合，按营收规模排名位列全球生物医药企业第18位，专注于研发、生产及商业化创新生物药物，为全球患者提供优质治疗选择。
Envista Holdings Corp是一家总部位于美国的企业，旗下Envista Forensics业务板块面向保险、法律及风险管理行业，在全球范围内提供法务工程与事故复原解决方案。公司前身为LWG咨询有限公司，2017年正式更名为Envista Forensics。
AMGN vs NVST — 直观对比
营收规模更大
AMGN
是对方的13.1倍
$750.6M
营收增速更快
NVST
高出6.4%
8.6%
净利率更高
AMGN
高出9.1%
4.4%
自由现金流更多
AMGN
多$869.3M
$91.7M
两年增速更快
AMGN
近两年复合增速
9.7%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $9.9B | $750.6M |
| 净利润 | $1.3B | $32.9M |
| 毛利率 | 69.8% | 54.7% |
| 营业利润率 | 27.6% | 9.8% |
| 净利率 | 13.5% | 4.4% |
| 营收同比 | 8.6% | 15.0% |
| 净利润同比 | 112.6% | 2641.7% |
| 每股收益（稀释后） | $2.45 | $0.20 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMGNNVST
| Q4 25 | $9.9B | $750.6M | ||
| Q3 25 | $9.6B | $669.9M | ||
| Q2 25 | $9.2B | $682.1M | ||
| Q1 25 | $8.1B | $616.9M | ||
| Q4 24 | $9.1B | $652.9M | ||
| Q3 24 | $8.5B | $601.0M | ||
| Q2 24 | $8.4B | $633.1M | ||
| Q1 24 | $7.4B | $623.6M |
净利润AMGNNVST
| Q4 25 | $1.3B | $32.9M | ||
| Q3 25 | $3.2B | $-30.3M | ||
| Q2 25 | $1.4B | $26.4M | ||
| Q1 25 | $1.7B | $18.0M | ||
| Q4 24 | $627.0M | $1.2M | ||
| Q3 24 | $2.8B | $8.2M | ||
| Q2 24 | $746.0M | $-1.2B | ||
| Q1 24 | $-113.0M | $23.6M |
毛利率AMGNNVST
| Q4 25 | 69.8% | 54.7% | ||
| Q3 25 | 67.8% | 55.3% | ||
| Q2 25 | 67.2% | 54.2% | ||
| Q1 25 | 63.6% | 54.5% | ||
| Q4 24 | 65.7% | 57.1% | ||
| Q3 24 | 61.1% | 52.8% | ||
| Q2 24 | 61.4% | 51.6% | ||
| Q1 24 | 57.0% | 57.1% |
营业利润率AMGNNVST
| Q4 25 | 27.6% | 9.8% | ||
| Q3 25 | 26.4% | 8.6% | ||
| Q2 25 | 28.9% | 6.8% | ||
| Q1 25 | 14.5% | 6.3% | ||
| Q4 24 | 25.4% | 7.1% | ||
| Q3 24 | 24.1% | 3.5% | ||
| Q2 24 | 22.8% | -182.2% | ||
| Q1 24 | 13.3% | 7.7% |
净利率AMGNNVST
| Q4 25 | 13.5% | 4.4% | ||
| Q3 25 | 33.7% | -4.5% | ||
| Q2 25 | 15.6% | 3.9% | ||
| Q1 25 | 21.2% | 2.9% | ||
| Q4 24 | 6.9% | 0.2% | ||
| Q3 24 | 33.3% | 1.4% | ||
| Q2 24 | 8.9% | -181.9% | ||
| Q1 24 | -1.5% | 3.8% |
每股收益（稀释后）AMGNNVST
| Q4 25 | $2.45 | $0.20 | ||
| Q3 25 | $5.93 | $-0.18 | ||
| Q2 25 | $2.65 | $0.16 | ||
| Q1 25 | $3.20 | $0.10 | ||
| Q4 24 | $1.17 | $0.00 | ||
| Q3 24 | $5.22 | $0.05 | ||
| Q2 24 | $1.38 | $-6.69 | ||
| Q1 24 | $-0.21 | $0.14 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $9.1B | $1.2B |
| 总债务越低越好 | $54.6B | $1.4B |
| 股东权益账面价值 | $8.7B | $3.1B |
| 总资产 | $90.6B | $5.7B |
| 负债/权益比越低杠杆越低 | 6.31× | 0.47× |
8季度趋势，按日历期对齐
现金及短期投资AMGNNVST
| Q4 25 | $9.1B | $1.2B | ||
| Q3 25 | $9.4B | $1.1B | ||
| Q2 25 | $8.0B | $1.1B | ||
| Q1 25 | $8.8B | $1.1B | ||
| Q4 24 | $12.0B | $1.1B | ||
| Q3 24 | $9.0B | $991.3M | ||
| Q2 24 | $9.3B | $1.0B | ||
| Q1 24 | $9.7B | $948.5M |
总债务AMGNNVST
| Q4 25 | $54.6B | $1.4B | ||
| Q3 25 | $54.6B | $1.4B | ||
| Q2 25 | $56.2B | $1.4B | ||
| Q1 25 | $57.4B | $1.4B | ||
| Q4 24 | $60.1B | $1.4B | ||
| Q3 24 | $60.4B | $1.4B | ||
| Q2 24 | $62.6B | $1.5B | ||
| Q1 24 | $64.0B | $1.5B |
股东权益AMGNNVST
| Q4 25 | $8.7B | $3.1B | ||
| Q3 25 | $9.6B | $3.1B | ||
| Q2 25 | $7.4B | $3.1B | ||
| Q1 25 | $6.2B | $3.0B | ||
| Q4 24 | $5.9B | $2.9B | ||
| Q3 24 | $7.5B | $3.1B | ||
| Q2 24 | $5.9B | $3.0B | ||
| Q1 24 | $5.0B | $4.1B |
总资产AMGNNVST
| Q4 25 | $90.6B | $5.7B | ||
| Q3 25 | $90.1B | $5.6B | ||
| Q2 25 | $87.9B | $5.7B | ||
| Q1 25 | $89.4B | $5.5B | ||
| Q4 24 | $91.8B | $5.4B | ||
| Q3 24 | $90.9B | $5.5B | ||
| Q2 24 | $90.9B | $5.4B | ||
| Q1 24 | $93.0B | $6.6B |
负债/权益比AMGNNVST
| Q4 25 | 6.31× | 0.47× | ||
| Q3 25 | 5.67× | 0.47× | ||
| Q2 25 | 7.57× | 0.46× | ||
| Q1 25 | 9.24× | 0.47× | ||
| Q4 24 | 10.23× | 0.48× | ||
| Q3 24 | 8.02× | 0.46× | ||
| Q2 24 | 10.57× | 0.51× | ||
| Q1 24 | 12.75× | 0.36× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.6B | $108.0M |
| 自由现金流经营现金流 - 资本支出 | $961.0M | $91.7M |
| 自由现金流率自由现金流/营收 | 9.7% | 12.2% |
| 资本支出强度资本支出/营收 | 6.5% | 2.2% |
| 现金转化率经营现金流/净利润 | 1.20× | 3.28× |
| 过去12个月自由现金流最近4个季度 | $8.1B | $230.4M |
8季度趋势，按日历期对齐
经营现金流AMGNNVST
| Q4 25 | $1.6B | $108.0M | ||
| Q3 25 | $4.7B | $78.7M | ||
| Q2 25 | $2.3B | $88.7M | ||
| Q1 25 | $1.4B | $300.0K | ||
| Q4 24 | $4.8B | $132.4M | ||
| Q3 24 | $3.6B | $70.7M | ||
| Q2 24 | $2.5B | $93.1M | ||
| Q1 24 | $689.0M | $40.3M |
自由现金流AMGNNVST
| Q4 25 | $961.0M | $91.7M | ||
| Q3 25 | $4.2B | $67.9M | ||
| Q2 25 | $1.9B | $76.4M | ||
| Q1 25 | $980.0M | $-5.6M | ||
| Q4 24 | $4.4B | $123.8M | ||
| Q3 24 | $3.3B | $63.3M | ||
| Q2 24 | $2.2B | $86.3M | ||
| Q1 24 | $459.0M | $29.3M |
自由现金流率AMGNNVST
| Q4 25 | 9.7% | 12.2% | ||
| Q3 25 | 44.4% | 10.1% | ||
| Q2 25 | 20.8% | 11.2% | ||
| Q1 25 | 12.0% | -0.9% | ||
| Q4 24 | 48.4% | 19.0% | ||
| Q3 24 | 39.0% | 10.5% | ||
| Q2 24 | 26.5% | 13.6% | ||
| Q1 24 | 6.2% | 4.7% |
资本支出强度AMGNNVST
| Q4 25 | 6.5% | 2.2% | ||
| Q3 25 | 4.6% | 1.6% | ||
| Q2 25 | 4.0% | 1.8% | ||
| Q1 25 | 5.0% | 1.0% | ||
| Q4 24 | 4.1% | 1.3% | ||
| Q3 24 | 3.0% | 1.2% | ||
| Q2 24 | 2.8% | 1.1% | ||
| Q1 24 | 3.1% | 1.8% |
现金转化率AMGNNVST
| Q4 25 | 1.20× | 3.28× | ||
| Q3 25 | 1.46× | — | ||
| Q2 25 | 1.59× | 3.36× | ||
| Q1 25 | 0.80× | 0.02× | ||
| Q4 24 | 7.61× | 110.33× | ||
| Q3 24 | 1.26× | 8.62× | ||
| Q2 24 | 3.30× | — | ||
| Q1 24 | — | 1.71× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMGN
| Products | $9.4B | 95% |
| Xgeva | $291.0M | 3% |
| Vectibix | $163.0M | 2% |
| Aranesp | $115.0M | 1% |
NVST
| Other | $375.8M | 50% |
| Specialty Productsand Technologies | $188.4M | 25% |
| Equipmentand Consumables | $186.4M | 25% |
